Alnylam Pharmaceuticals, Inc. (ALNY) Income Statement Analysis

See more : Kaimei Electronic Corp. (2375.TW) Income Statement Analysis – Financial Results

Complete financial analysis of Alnylam Pharmaceuticals, Inc. (ALNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alnylam Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

DNO ASA (DNO.OL) Income Statement Analysis – Financial Results
NOCIL Limited (NOCIL.BO) Income Statement Analysis – Financial Results
Beijing SinoHytec Co., Ltd. (688339.SS) Income Statement Analysis – Financial Results
China Overseas Land & Investment Limited (CAOVF) Income Statement Analysis – Financial Results
Central China Securities Co., Ltd. (601375.SS) Income Statement Analysis – Financial Results

Alnylam Pharmaceuticals, Inc. (ALNY)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.alnylam.com

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	1.83B	1.04B	844.29M	492.85M	219.75M	74.91M	89.91M	47.16M	41.10M	50.56M	47.17M	66.73M	82.76M	100.04M	100.53M	96.16M	50.90M	26.93M	5.72M	4.28M	176.00K	0.00
Cost of Revenue	310.41M	168.82M	140.14M	78.05M	25.06M	1.80M	13.37M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	1.52B	868.60M	704.14M	414.80M	194.69M	73.11M	76.55M	47.16M	41.10M	50.56M	47.17M	66.73M	82.76M	100.04M	100.53M	96.16M	50.90M	26.93M	5.72M	4.28M	176.00K	0.00
Gross Profit Ratio	83.02%	83.73%	83.40%	84.16%	88.60%	97.59%	85.13%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Research & Development	1.00B	883.02M	792.16M	654.82M	655.11M	505.42M	390.64M	382.39M	276.50M	190.25M	112.96M	86.57M	99.30M	106.38M	108.73M	96.88M	120.69M	49.80M	35.32M	24.60M	13.10M	3.34M
General & Administrative	795.65M	770.66M	620.64M	588.42M	479.01M	382.36M	199.37M	89.35M	60.61M	44.53M	27.15M	44.61M	38.28M	37.73M	39.91M	27.12M	23.39M	16.63M	13.87M	11.94M	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	795.65M	770.66M	620.64M	588.42M	479.01M	382.36M	199.37M	89.35M	60.61M	44.53M	27.15M	44.61M	38.28M	37.73M	39.91M	27.12M	23.39M	16.63M	13.87M	11.94M	7.53M	880.00K
Other Expenses	0.00	-109.37M	-2.05M	45.53M	20.73M	4.17M	-3.02M	6.17M	76.00K	1.82M	-47.00K	331.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	1.80B	1.65B	1.41B	1.24B	1.13B	887.78M	590.00M	471.75M	337.11M	234.78M	140.11M	131.18M	137.58M	144.11M	148.64M	124.00M	144.07M	66.43M	49.19M	36.54M	20.62M	4.22M
Cost & Expenses	2.11B	1.82B	1.55B	1.32B	1.16B	889.58M	590.00M	471.75M	337.11M	234.78M	140.11M	131.18M	137.58M	144.11M	148.64M	124.00M	144.07M	66.43M	49.19M	36.54M	20.62M	4.22M
Interest Income	95.56M	24.81M	1.58M	11.81M	33.45M	29.26M	12.24M	8.31M	5.86M	2.56M	1.07M	977.00K	1.21M	2.31M	5.39M	14.41M	15.39M	0.00	0.00	0.00	0.00	0.00
Interest Expense	121.22M	155.97M	143.02M	84.50M	0.00	29.26M	12.24M	8.31M	5.86M	2.56M	1.07M	977.00K	1.21M	2.31M	5.39M	872.00K	1.08M	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	54.05M	44.47M	47.57M	34.77M	17.18M	6.44M	13.37M	15.13M	19.05M	11.93M	10.23M	9.04M	5.13M	4.94M	5.99M	5.73M	4.08M	3.82M	3.12M	2.44M	838.00K	36.00K
EBITDA	-258.24M	-926.56M	-661.56M	-736.33M	-868.08M	-754.24M	-488.19M	-409.46M	-276.96M	-172.29M	-82.71M	-51.71M	-49.69M	-38.06M	-41.02M	-18.93M	-75.06M	-35.69M	-38.83M	-29.55M	-19.61M	-4.19M
EBITDA Ratio	-14.12%	-86.22%	-83.99%	-156.46%	-427.50%	-1,115.02%	-556.20%	-900.33%	-720.27%	72.29%	-197.05%	-23.29%	-65.60%	-50.45%	-47.38%	-23.62%	-174.50%	-131.57%	-705.58%	-691.61%	-8,507.39%	0.00%
Operating Income	-282.18M	-785.07M	-708.65M	-828.44M	-939.43M	-814.67M	-500.09M	-424.59M	-296.01M	-404.98M	-92.94M	-129.46M	-54.82M	-44.07M	-48.11M	-27.84M	-93.18M	-39.50M	-43.47M	-32.26M	-25.06M	-4.22M
Operating Income Ratio	-15.43%	-75.68%	-83.93%	-168.09%	-427.50%	-1,087.56%	-556.20%	-900.33%	-720.27%	-800.97%	-197.05%	-194.01%	-66.24%	-44.05%	-47.86%	-28.95%	-183.07%	-146.68%	-760.53%	-754.18%	-14,236.93%	0.00%
Total Other Income/Expenses	-151.34M	-341.92M	-143.49M	-27.16M	54.18M	54.00M	9.21M	14.48M	5.94M	4.38M	1.02M	12.87M	-2.83M	1.07M	1.10M	2.31M	12.96M	4.89M	558.00K	-390.00K	-4.64M	0.00
Income Before Tax	-433.52M	-1.13B	-852.14M	-855.60M	-885.25M	-760.67M	-490.87M	-410.11M	-290.07M	-400.60M	-91.92M	-116.59M	-57.65M	-43.00M	-47.01M	-25.53M	-80.22M	-34.61M	-42.91M	-35.37M	-29.69M	0.00
Income Before Tax Ratio	-23.71%	-108.63%	-100.93%	-173.60%	-402.85%	-1,015.48%	-545.95%	-869.63%	-705.83%	-792.32%	-194.88%	-174.73%	-69.66%	-42.98%	-46.76%	-26.55%	-157.61%	-128.51%	-750.77%	-826.72%	-16,871.59%	0.00%
Income Tax Expense	6.73M	4.16M	680.00K	2.68M	863.00K	823.00K	-25.60M	-23.44M	-24.91M	-40.21M	-2.70M	-10.57M	-5.80M	514.00K	582.00K	719.00K	5.25M	-4.89M	-558.00K	390.00K	4.59M	-86.00K
Net Income	-440.24M	-1.13B	-852.82M	-858.28M	-886.12M	-761.50M	-490.87M	-410.11M	-290.07M	-360.40M	-89.23M	-106.01M	-57.65M	-43.52M	-47.59M	-26.25M	-85.47M	-34.61M	-42.91M	-32.65M	-25.03M	-4.14M
Net Income Ratio	-24.08%	-109.04%	-101.01%	-174.15%	-403.24%	-1,016.58%	-545.95%	-869.63%	-705.83%	-712.79%	-189.17%	-158.88%	-69.66%	-43.50%	-47.34%	-27.30%	-167.92%	-128.51%	-750.77%	-763.30%	-14,223.30%	0.00%
EPS	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57	-5.42	-4.79	-3.45	-4.85	-1.45	-2.11	-1.36	-1.04	-1.14	-0.64	-2.21	-1.09	-1.96	-2.75	-26.56	-12.48
EPS Diluted	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57	-5.42	-4.79	-3.45	-4.85	-1.45	-2.11	-1.36	-1.04	-1.14	-0.64	-2.21	-1.09	-1.96	-2.75	-26.56	-12.48
Weighted Avg Shares Out	124.91M	121.69M	118.45M	114.99M	109.26M	100.59M	90.55M	85.60M	83.99M	74.28M	61.55M	50.29M	42.41M	42.04M	41.63M	41.08M	38.66M	31.89M	21.95M	11.89M	942.67K	331.34K
Weighted Avg Shares Out (Dil)	124.91M	121.69M	118.45M	114.99M	109.26M	100.59M	90.55M	85.60M	83.99M	74.28M	61.55M	50.29M	42.41M	42.04M	41.63M	41.08M	38.66M	31.89M	21.95M	11.89M	942.67K	331.34K

What Makes Alnylam (ALNY) a New Buy Stock

December 4, 2024zacks.com

Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

November 27, 2024businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the...

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

November 26, 2024zacks.com

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

November 25, 2024businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in...

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

November 18, 2024zacks.com

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

November 17, 2024businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR)...

Alnylam downgraded to Underperform from Peer Perform at Wolfe Research

November 11, 2024https://thefly.com

Wolfe Research downgraded Alnylam to Underperform from Peer Perform, citing "unfriendly channel dynamics coupled with inability to rebate."

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 4, 2024businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT (11:45 ET) at...